colorectal cancer (CRC) is the third most common diagnosed and the second deadliest malignancy among men and women combined. CRC has both strong environmental-related and genetic risk factors. CRC encompasses a very heterogeneous group of diseases caused bydifferent mutations and mutagens. Not all CRCs share similar driving mutations, making it difficult to develop molecular 'catch-all' therapies. Surgery continues to be the mainstay of treatment for early diagnosis, but it is no longer effective in advanced metastatic disease, which accounts for approximately 25% of diagnoses. Significant improvements in the treatment of advanced colorectal cancer have been achieved over the past ten years. The treatment of metastatic colorectal cancer with numerous cytotoxic drugs and targeted therapies has improved median overall survival in clinical studies to more than 30 months.